TaeWoong Medical USA Receives FDA 510(k) Clearance for SPAXUS™, Expanding Its EUS Therapeutic Portfolio
The FDA determined the SPAXUS™ Stent to be substantially equivalent to legally marketed predicate devices, allowing for commercialization in the United States
May 1, 2026